top border
top border
Featured Programs
PD-L1 Expression as a Biomarker in RCC
The panelists, Nizar M. Tannir, MD, FACP; Carlos H. Barrios, MD; Susanne Osanto, MD, PhD; Daniel Heng, MD, MPH, FRCPC; and Paul Nathan, MBBS, PhD, FRCP, address PD-L1 expression as a potential biomarker for selecting renal cell carcinoma (RCC) treatment. View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Featured Video
Novel Combination Approaches for Metastatic Kidney Cancer
Geoffrey Thomas Gibney, MD; Ryan J. Sullivan, MD; Hussein A. Tawbi, MD, discuss advances in BRAF-targeted therapy for patients with metastatic melanoma. View now
Gina Columbus

Gina Columbus highlights the latest news in oncology in this week's OncLive News Network.

Publication Bottom Border
Border Publication
x